Milestone Pharmaceuticals Inc.
MIST Healthcare Biotechnology
Milestone Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 million, up 54.6% from fiscal 2023. In the quarter to June 2026, revenue fell 62.7%, EPS fell 5.00%, free cash flow fell 80.8% and total debt rose 7.19%, each against the same quarter a year earlier.
Follow MIST
Milestone Pharmaceuticals Inc. (MIST) EV/Sales
As of 16 October 2026, Milestone Pharmaceuticals Inc. (MIST) trades at a EV/Sales of −2.4×. Over the past ten years it has ranged from −2.4× (October 2026) to 25.7× (April 2026) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 5.7× | 97.54% |
| FY2023 | 2.9× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 14.1× | 202.14% |
| Mar 2026 | 4.7× | (15.21%) |
| Mar 2023 | 5.5× | — |
| Dec 2022 | 0.0× | — |
| 2 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MIST Milestone Pharmaceuticals Inc. | −2.4× |
| PMVP PMV Pharmaceuticals, Inc. compare | n/m |
| IMUX Immunic, Inc. compare | n/m |
| PYPD PolyPid Ltd. compare | n/m |
| BDTX Black Diamond Therapeutics, Inc. compare | n/m |
| UNCY Unicycive Therapeutics, Inc. compare | n/m |
| NRXS Neuraxis, Inc. compare | 16.0× |
| CBUS Cibus, Inc. compare | 18.9× |
| ATRA Atara Biotherapeutics, Inc. compare | 20.7× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)